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IWeS27I Relation between superantigen-induced
inflammatory cytokines severity of invasive group A
streptoeoeeal infections
Anna Norrby-Teglund
Karolinska Institute, Div. of Infectious Diseases, Huddinge, Sweden Hospital
Cytokines elicited by bacterial superantigens have been suggested to playa
central role in severe systemic clinical manifestations ofgram-positive sepsis.
Analyses of in vivo and in vitro cytokine responses in patients with severe
(streptococcal toxic shock syndrome and/or necrotizing fasciitis) or non-
severe (no toxic shock or deep-tissue involvement) group A streptococcal
invasive infection revealed a direct correlation between cytokine responses
and severity ofinvasive group A streptococcal disease. Significantly elevated
frequencies of pro-inflammatory cytokines were observed in acute phase
peripheral blood mononuclear cells from severe cases as compared to non-
severe cases. Similarly. in vivo inflammatory eytokine responses were
markedly higher in tissue biopsies of patients with necrotizing fasciitis
than in severe cellulitis/limited necrosis. Importantly. this difference in in
vivo cytokine responses during acute phase could be reproduced when paired
age and sex-matched severe and non-severe cases infected with a clonal
streptococcal strain were tested in vitro during their convalescent phase for
immune response to culture supernatants from their infecting isolate. Thus.
our data indicate that inherent host factors determine the magnitude of
cytokine responses to streptococcal superantigens. and consequently the
clinical outcome of infection. The importance of host factors, specifically
HLA class II, was further supported by in vitro experiments using cells
transfected with previously identified risk- and protective HLA class II
molecules. inasmuch as the risk HLA alleles promoted significantly stronger
responses to streptococcal superantigen than did the protective alleles.
529 - Antimicrobial resistance - evolution and ...
IWeS31 I Role of mutator alleles in the generation of multi-
resistant strains
D. Bregeon. E. Denamur, M. Fons, A. Giraud. B. Godelle. I. Matic. B.
Picard, M. Radman. F. Taddei, P. Taillez. O. Tenaillon
Genetique Moleculaire Evolutive et Medicale E9916 INSERM, Paris, France
As WHO stated in one of its report. "every bacteria possess an inherent
flexibility that enables them sooner or later to evolve antimicrobial resistance
genes". To be able to take into account some of this flexibility. we have
developed a multidisciplinary network including MDs. population geneti-
cists. ecologists and molecular biologists. Among natural isolates ofE. coli
and Salmonella the mutation rates to antibiotic resistance are higly variable
(LeClerc et al. 1996 Matic et al. 1997). Mutator alleles. such as mismatch
repair deficiency. can enhance up to lOOO-fold mutation and recombination
rate (Vulic et al. 1997).
Modelling (Taddei et al. 1997b) and experimental evolution (Chao and
Cox. 1983; Mao et al. 1997; Sniegowski et al. 1997) can show that such a high
mutation rate can be favoured and speed up bacterial adaptation to new
challenges (Taddei et al. 1997a) such as antibiotic treatment thus generating
multiresistant strains.
IWeS33IEvolution to ameliorate the biological costs of
antibiotic resistance
J. Bjorkmanl •2• I. Nagaev2• O. G. Berg2, D. Hughes2• D. I. Anderssonl
1Swedish Institute for Infectious Disease Control, Solna; 2Uppsala, Sweden
University
The frequency ofantibiotic resistance in a bacterial population is. apart from
the volume ofantibiotic use. mainly determined by the fitness and transmis-
sion costs of resistance combined with the ability of the resistant bacteria to
compensate for these costs by mutations. Most resistances decrease bacterial
fitness as measured by competition experiments between sensitive and
resistant strains in the absence of antibiotic. These costs can be reduced by
compensatory mutations without any loss ofresistance. Recent results show
that the rate and nature of the compensatory mutations is strongly affected
by the growth environment. Thus, streptomycin- and fusidic acid resistant
Salmonella typhimurium that evolve in mice or laboratory medium obtain
different compensatory mutations. These differences in mutation spectra are
caused either by an environment-specific formation or selection of the
compcnsated mutants. These results suggest that the evolution to ameliorate
the costs ofantibiotic resistance may follow different trajectories within and
outside a bacterial host.
530 - Vaccines in pregnancy and infancy
IWeS36! BCG vaccination
Hans L. Rieder
International Union Agaillst Tuberculosis and Lung Disease, Paris, France
The Bacille Calmette-Guerin (BCG) vaccine. for the first time administered
by WeillHalle to a newborn child exposed to an infectious parent in July
1921 with no adverse outcome found its application rapidly spreading
within a few years. The initial indication was limited to newborn children
exposed closely to a parent with infectious tuberculosis and shown to reduce
fatality from childhood tuberculosis by some 80 per cent. Once safety ofthe
vaccine was established. the indication was expanded to children in general.
and the parenteral administration replaced the original oral vaccination
without loss ofefficacy. Today. BCG has cumulatively been given to more
children than any other vaccine. yet its value in the control of tuberculosis
remains circumspect. The vaccine has undergone several genetic mutations
and various strains of BCG exist today. and thc protection it affords varies
greatly in different situations. The IS-year follow-up results of the largest
every conducted trial. in Chingleput, South India. have just been published
and shown no protection against bacteriologically confirmed tuberculosis.
On the other extreme. BCG continues to provide. e.g.• high protection in
British school children. A variety ofhypotheses have been offered to provide
possible explanations for this variation in protective efficacy, yet none is fully
satisfactory. What is rather consistent, however, is the original notion that
BCG vaccination provides considerable protection against a fatal outcome
from serious forms of childhood tuberculosis. Its impact on the epidemio-
logical situation of tuberculosis is, on the other hand, generally accepted to
be minimal. Policy decisions on the use ofBCG must thus take into account
the frequency ofserious. not otherwise preventable forms of tuberculosis in
children versus the frequency ofadverse reactions (albeit infrequent), and the
desirability to preserve the usefulness of the tuberculin skin test in contact
investigations. as well as cost-effectiveness ofits continued use. The variation
in protective efficacy in different areas of the world would ideally require an
assessment ofits value through case-control studies in each setting faced with
a decision on the continuation or abolition of its use in routine practice,
coupled with an analysis of its cost-effectiveness.
IWeS37I Conjugate vaccines allow earlier administration of
polysaccharide vaccines
Rino Rappuoli
IRIS, Chiron SpA, Siena, Italy
Many pathogenic bacteria. including N. meningitidis, S. pneumoniae, type B
H. influenzae, produce a polysaccharide capsule that is made by many
repeating units of a simple sequence of one or more sugars. Vaccines
containing purified. high molecular weight polysaccharides induce protec-
tive immunity in adults. They were introduced in the 70s and are available
against meningococcus and pneumococcus. These vaccines induce a T-cell-
independent immunity. because polysaccharides are unable to bind the T-
cell receptor and therefore stimulate only B cells. T-cell-independent
vaccines induce an IgM-mediated antibody response that cannot be boosted
by subsequent immunizations and is effective only after two years ofage. In
infants polysaccharide vaccines usually do not work at all. To overcome the
limit of the T-cell independence of this type of vaccines. bacterial poly-
saccharides or oligosaccharides containing many repeating units have been
chemically coupled to T-cell-dependent protein antigens. The resulting
semisynthetic conjugate vaccines are T-cell-dependent and induce an 19G-
based immune response and memory. so that it can be boosted by subsequent
infection and immunization. Moreover. the conjugate vaccines have the
great advantage of working in infants below two years of age. The
development of conjugate vaccines allowed the introduction of mass
vaccination of infants against H. influenzae, that has been one of the most
successful vaccinations introduced during the last decade. In five years this
vaccination has virtually eliminated infant meningitis caused by H. inftuen-
zae in the USA and all countries where vaccination has been introduced.
Clinical trials are presently ongoing with conjugate vaccines against menin-
gococcus A and C and against the most common serotypes of pneumococ-
cus. The... vaccines will be introduced within a few ye~rs ~nd ~re expected to
eradicate most causes ofbacterial meningitis. A polysaccharide vaccine ba""d
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on the Vi antigen has been developed also against S. ryphi. Conjugate
vaccines are being tested against Salmonella and Shigella.
531 - Osteomyelitis
Mt~ Diagnosis and management of the infected joint
prosthesis
D. Osmon
Mayo Clinic, Rochester, Minnesota, United States
The risk ofprosthetic joint infection (I'JI) in the more than 430.000 total hip
and total knee arthroplasties performed in the United States each year is low
(1-4%). The incidence rate ofPJI is highest in the first two years following
prosthesis implantation. but has occurred as late as 20 years following
implantation. In the majority of cases. pJI is due to Sraphylococcus aureus,
coagulase negative staphylococci and B-hemolytic streptococci. Infections
due to other organisms occur much less frequently. Most infections arc
thought to occur as a consequence of intraoperative contamination of the
prosthesis. Hematogenous seeding uf the prosthesis is much less commun.
This talk will focus on the epidemiology. diagnosis. treatment and
prevention of pJI. Topics that will be discussed include new classification
schemes for I'JI, information regarding risk factors for I'JI. as well as selected
cuntroversies in the medical and surgical management of I'JI. These COI1-
truversies include the role of debridement and retention of the prosthesis.
given recent data regarding the treatment of staphylococcal I'JI without
prosthesis removal using antimicrobial combinations that include rifampin.
Lastly. strategies to prevent I'JI in the preoperative. intraoperative and
postoperative period will be reviewed. including a summary of new
consensus guidelines for the use of antibiotic prophylaxis to prevent PJI
due to ural flora following dental procedures.
IWeS40 I The use of quinolones and rifampin for the
treatment of infected orthopedic devices
W. Zimmerli. P. E. Ochsner
Medical University Clinic ami Orrhopedic Clinic, KatltotlSspital, Liestal,
Switzerland
Infections. mostly caused by Sraphylococcus aurel/s or coagulase-negative
staphylococci. arc feared complication in orthopedic surgery. Betalactams
are not a good choice for long-term oral treatment of device-related
infections, bCC'3USC of their lack of activity on sJow-groVY'ing bacteria, and
their unfavorable bioavailability. Therefore. the treatment with quinolone/
rifampin has been studied in patients with infected orthopedic devices. In
observational studies. the success-rate was 62% (13/21) (AAC 37: 1214.
1993). and 82% (9/11) (CID 14: 1251. 1992) with retention ofthe device. In a
randomized. placebo-controlled study comparing ciprofloxacin/rifampin vs
ciprofloxacin/placebo. the superiority of the rifampin-regimen has been
documented with cure-rates of 100% (12/12) vs 58% (7/12) (JAMA 279:
1537. 1998). Such high cure-rates can only be obtained. if patients are
carefully selected. Prerequisites for long-term (3-6 months) treatment with
retention of the device are as follows: (I) early manifestation « 3 months)
or hematogeneous infection with a short history « 1 month). (2) stable
implant. (3) rifampin- and quinolone-susceptible staphylococci. (4) good
condition of bone stock and soft tissue (no sinus tract). (5) debridement
surgery. In patients with sinus tracts. quinolone/rifampin treatment should
not be given. because of the risk of exogenous superinfection with quino-
lone/rifampin resistant microorganisms. Before the explantation of the
device. such patients should be treated with either flucloxacillin or a
glycopeptide, according to the susceptibility of the staphylococci. The
quinolone/rifampin regimen should be started only after reimplantation in
a 2-stage exchange. Long-term therapy with quinolone plus rifampin is
expensive and may cause adverse events (nausea. anorexia). Therefore. only
microbiologically documented cases should be treated with this regimen. In
conclusion. the quinolone/rifampin-regimen is higWy efficacious. ifpatients
are carefully selected.
IWeS411 The use of antibiotic-containing bead chains in the
treatment of chronic bone infections
K.Klemm
B.G. Unfallklinik FrankfUrt/Main, Cffmany
Objectives: By application of Gentamicin PMMA bead chains into osteo-
myelitic cavities a local antibiotic therapy in concentrations far above the
MIC of most common pathogens can be execuded.
Methods: The bone cement PMMA serves as carrier material for the
protracted release of the antibiotic. In in vitro studies of WaWig et al. up
to 600 JLg/ml were measured by elution in the buffer solution on the 1st day
and on the 80th day there were still 10 JLg/ml gentamicin per bead in the
eluate. Under clinical conditions 80 to 200 JLg/ml ofGentamicin were found
in the wound secretion depending on the number ofimplanted beads. With
such high concentrations at the infection site the MIC breakpoint of
Gentamicin 4 JLg/ml were exceeded locally by a factor of more than 10
whereas only low concentrations were found in the serum and urine.
Nephrotoxic and ototoxic side effects arc not to be feared.
Surgical procedure: After debridement of all infected and devitalized
tissue the infected cavity is filled completely with the Gentamicin PMMA
chains. For high local concentrations primary wound closure is dispensable.
The chains are removed by extraction within 7 days or when a second
operation as bone grafting is indicated
Results: In 405 cases of temporary filling ofosteomyelitis cavities presented
at the 13th. Int. Congress of Chemotherapy 1983 in Vienna the success rate
was 96%.
conclusion: Gentamicin PMMA chains are effective and save in the opera-
tive treatment of chronic osteomyelitis of all forms.
5G02 - ESGEM
IMoG2-11 Genetic markers: can molecular typing reveal an
epidemiological association?
M. C. J. Maiden
WeI/come Trl/st Centre for the Epidemiology of lrifectiol/s Disease. Department
of Zoology, University ofOxford, South Parks Road Oxford, United Kingdom
Bacterial epidemiology requires precise isolate characterisation. The tech-
niques used to achieve this should combine appropriate levels ofdiscrimina-
tion with cost effectiveness and reproducibility. Increasingly. serological
typing schemes are being replaced with molecu1ar techniques, which often
employ fingerprinting approaches. Unfortunately. many novel techniques
are of limited value because they fail to take into account the population
structure of the bacterial species under investigation. This talk will provide
an overview of bacterial population biology and describe how the insights
obtained from this subject can be exploited in the development ofeffective
isolate characterisation techniques and in the investigation of bacterial
epidemiology.
IMoG2-21 Evaluation of endemic nosocomial transmission
and sources of infection with the help of molecular typing
D. S. Blanc
Centre Hospitalier Universitaire Va'4dois, 1011 Lausanne, Switzerland
While molecular typing methods are widely used to help the hospital
epidemiologist in the investigation of nosocomial outbreaks, their use for
the understanding of endemic nosocomial infections has been limited. The
identification of the source or reservoir is only possible with comprehensive
screening of the environment and the endogenous flora ofpatients and staff.
and therefore requires significant resources. However. cross-eontarnination
or the existence of a common exogenous source might be investigated
typing clinical isolates during non epidemic periods. Cross-eontamination is
suspected when isolates from different patients belong to the same type and
when an epidemiological relation can be established. Studies performed with
the three main nosocomial pathogenes. StaphylococClls al/rel/S, Escherichia coli
and Pseudomonas aeruginosa, have revealed complex situations which may
vary from one setting to another. While some data suggest that pre-existing
colonization at admission is the major source ofmicroorganisms responsible
for nosocomial infections. other shows that exogenous sources or cross-
contamination may account for an important part of these infections.
According to these studies. the proportion of isolates presumably acquired
through cross-eontamination or exogenous source may vary from 10 to
60% for P. arfllgillosa and from 0 to 21 % for E. coli. The situation ofS. aureus
is complex because of the existence ofclones which may be higWy prevalent
in the population. with no apparent epidemiological link. Some data
suggest, that the proportion of cross-eontamination is lower for methicil1in
susceptible S. aI/tellS than for MRSA. This property for dissemination has
alsu been described ti" other multiresistant nosocomial pathugen•.
